Mary Joyce B. Wingler PHARMD, BCIDP


The ART of Implementing an Antiretroviral Stewardship Program

By addressing ART-related medication errors and increasing linkage to care, antiretroviral stewardship programs can improve management of inpatients with HIV.

T. Sam Albanesi, MD, MA


An Update on Lenacapavir

This new antiretroviral with a unique mechanism of action may be lifesaving for those with treatment-resistant HIV infection.

Jessica Malaty Rivera, MS


Why Aren’t We Better Protecting Our Youngest Children Against Infections?

Vaccinations and mitigations for COVID-19 and other respiratory viruses have not been made a priority for young children. Let’s change this before the next big surge hits.

Nisha Patel, PharmD, BCPS


To Prophylax or not to Prophylax: Preventing CDI

Clinicians look at optimal approaches for trying to avoid Clostridioides difficile infection (CDI).

Alison L. Blackman, PharmD, BCIDP


So You Made the Decision to Implement Vancomycin AUC Dosing. Now What?

Since the vancomycin guideline update, institutional leaders have been faced with the challenge of implementing and monitoring AUC-guided dosing.

Brandon Dionne, PharmD, BCPS-AQ ID, BCIDP, AAHIVP


Going Viral on Social Media: Integrating Digital Tools into Pharmacy Rotations

In the latest Bench to Bedside column, 2 clinicians discuss the benefits of utilizing social media for learning.

Jesse S. Veisblatt, MD


Bad Bugs, New Drugs: A Discussion of Selected New Therapeutics From IDWeek 2022

Cefepimetaniborbactam may represent a safe and effective carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.

Dana Holger, PharmD, MPH, AAHIVP


Tricky Infusion Issues and Potential Solutions: OPAT Edition

Outpatient parenteral antimicrobial therapy (OPAT) offers benefits for patients as well as providing cost effectiveness; however, it is not without its challenges. Two clinicians provide insights on this modality.

Brandon Garcia, PharmD, PGY2


New Recommendations for Antibiotic Prophylaxis Prior to Dental Procedures

The American Dental Association (ADA) has updated patient profiles on who should be indicated for antibiotic prophylaxis.

Sarah Green, PharmD, BCPS, BCIDP, AAHIVP


Precision Dosing of To-Marrow: Linezolid Therapeutic Drug Monitoring

Emerging literature suggests therapeutic drug monitoring for this antimicrobial to minimize the risk for linezolid-associated toxicities while maintaining efficacy in select populations.

Theodore S. Rader IV, MD, MS


Will We Ever See Oral Carbapenems for ESBL Urinary Tract Infections?

Recent issues surrounding the ADAPT-PO and SURE-2 trials place the spotlight on the difficulties developing oral carbapenem-based antibiotics and case their future into doubt.

Christina Yen, MD; Ahmed Abdul Azim, MD; and Preeti Mehrotra, MD, MPH


From Single-Use to Multi-Use: A Brief Review of N95 Respirator Decontamination Strategies

This indispensable personal protective equipment did come up in short supply and reuse strategies has become a topic of great interest and research.

Nina Cosdon


Unveiling Gender Disparities in Lyme Disease: A Critical Analysis of Persistent Illness

Very few Lyme disease studies consider sex- and gender-based differences. Is this flawing the research?

Kaitlyn Jarrell, PharmD, BCPS, AAHIVP


PrEP State of the Union: Adherence, Access, Uptake Issues

Although this form of prophylaxis is highly protective, there are situations in which breakthrough infections occur.

Steven P. LaRosa, MD


CDC Presents Core Elements for Sepsis Programs

This new program from the federal agency can be viewed as a useful starting point for the development and assessment tool for sepsis programs with more granularity required.

Geena Kludjian, PharmD, BCIDP


Employee Health After the COVID-19 Pandemic: Stronger Than Yesterday

For providers on the front lines, lessons learned can help inform strategies to enhance the protection of their health going forward.

Olivia Mobarakai, DO


Where Do We Draw the Line? Duration of Antibiotic Therapy Varies for Bloodstream Infections

With potential delays in treatment, bloodstream infections can be concerning for clinicians. Here is a review of the literature that offer guidance for treatment.

Victoria Grant, PharmD


Strengths and Limitations of T2Candida Implementation From an Antimicrobial Stewardship Perspective

This novel, rapid diagnostic assay uses polymerase chain reaction and magnetic resonance to identify the 5 most common Candida species.

Daniel Chastain, PharmD, BCIDP, AAHIVP


Clinical Considerations in Conducting Antifungal Susceptibility Testing

Access to antifungal susceptibility testing (AFST) remains limited in the United States. Therefore, providers must recognize clinical situations where AFST will provide its greatest value. In the latest article from SIDP, infectious disease pharmacists offers some insights on this subject.

Connor Iapoce


Weekly Flu Report Finds Sporadic Infections

This flu season, the CDC reported at least 2.4 million flu illnesses, 23,000 hospitalizations, and 1,400 deaths from flu so far.

Malki De Silva, MPH


Recent Research Indicates That We're Falling Short on HBV Elimination Targets

Organizations look at an agent-based model to assess the impact of vaccination, screening, and treatment on incidence and prevalence of HBV in Ontario, Canada.

Rick Starlin, MD


The Variety of Variants in COVID-19

The evolution of the major variants, including the delta mutation.

Kevin Michael Reiter, MD, PA


Practice Pearls for Treatment of Respiratory Infections

Tina Tan, MD; Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; Priya Nori, MD; Jacinda Abdul-Mutakabbir, PharmD; and Kevin Michael Reiter, MD, PA, provide key takeaways from the discussion on the treatment of respiratory viral infections.

Victoria Johnson


HIV CRISPR Therapy Fast-Tracked by the FDA

The phase 1/2 trial evaluating EBT-101 dosed its first patient in September 2022.

Tracy Zembles, PharmD


Expanded Treatment Options for Multi-Drug Resistant Infections in Children

In the latest article from SIDP, here is a look at therapy options addressing this emerging clinical challenge.

Alexandra Hanretty, PharmD,


UTIs: Why Did You Have to Go and Make Things so Complicated?

Although hospitalizations due to urinary tract infections have increased, there are some investigational antibiotics in clinical trials. Here is a review of some of these therapies in the pipeline.

© 2023 MJH Life Sciences

All rights reserved.